Published in Brain Res on February 16, 2010
An animal model of cortical and callosal pathology in multiple sclerosis. Brain Pathol (2010) 0.97
Neuroimaging in multiple sclerosis: neurotherapeutic implications. Neurotherapeutics (2011) 0.85
Third ventricular enlargement in early stages of multiple sclerosis is a predictor of motor and neuropsychological deficits: a cross-sectional study. BMJ Open (2013) 0.84
Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients. PLoS One (2015) 0.83
Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations. Mult Scler Int (2013) 0.80
MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment. J Neurol (2014) 0.78
Width of 3. Ventricle: reference values and clinical relevance in a cohort of patients with relapsing remitting multiple sclerosis. Open Neurol J (2013) 0.78
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis. Neurol Ther (2016) 0.75
The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging (2016) 0.75
Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study. Neurology (2017) 0.75
Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NOS (NOS type II), and myelin proteins in animal model of multiple sclerosis. Arch Immunol Ther Exp (Warsz) (2017) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage (2006) 23.57
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med (2010) 13.70
Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage (2008) 12.12
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Large-scale automated synthesis of human functional neuroimaging data. Nat Methods (2011) 6.94
Network modelling methods for FMRI. Neuroimage (2010) 6.61
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Nonstationary cluster-size inference with random field and permutation methods. Neuroimage (2004) 4.41
Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci (2005) 4.00
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet (2009) 3.92
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Non-white noise in fMRI: does modelling have an impact? Neuroimage (2005) 3.61
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med (2012) 3.16
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke (2004) 3.07
Validating cluster size inference: random field and permutation methods. Neuroimage (2003) 3.03
Acquisition and voxelwise analysis of multi-subject diffusion data with tract-based spatial statistics. Nat Protoc (2007) 3.00
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet (2013) 2.89
Optimization of experimental design in fMRI: a general framework using a genetic algorithm. Neuroimage (2003) 2.80
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol (2012) 2.68
Meta-analysis of neuroimaging data: a comparison of image-based and coordinate-based pooling of studies. Neuroimage (2008) 2.54
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology (2014) 2.41
Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke (2007) 2.36
Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage (2010) 2.27
DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease. Neuroimage (2010) 2.10
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Everything you never wanted to know about circular analysis, but were afraid to ask. J Cereb Blood Flow Metab (2010) 2.05
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2012) 2.05
Functional connectomics from resting-state fMRI. Trends Cogn Sci (2013) 2.05
Combining voxel intensity and cluster extent with permutation test framework. Neuroimage (2004) 2.00
A comparison of random field theory and permutation methods for the statistical analysis of MEG data. Neuroimage (2005) 1.93
Diagnosis and exploration of massively univariate neuroimaging models. Neuroimage (2003) 1.91
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet (2010) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol (2008) 1.85
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Multi-site genetic analysis of diffusion images and voxelwise heritability analysis: a pilot project of the ENIGMA-DTI working group. Neuroimage (2013) 1.78
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Evaluating the consistency and specificity of neuroimaging data using meta-analysis. Neuroimage (2008) 1.73
Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol (2009) 1.73
Diffusion-weighted and perfusion MRI demonstrates parenchymal changes in complex partial status epilepticus. Brain (2005) 1.73
Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann Neurol (2008) 1.71
Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry (2009) 1.69
Impaired anatomical connectivity and related executive functions: differentiating vulnerability and disease marker in bipolar disorder. Biol Psychiatry (2013) 1.63
Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke (2006) 1.59
Switching attention and resolving interference: fMRI measures of executive functions. Neuropsychologia (2003) 1.58
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol (2010) 1.55
Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci (2006) 1.54
Linkage disequilibrium: ancient history drives the new genetics. Hum Hered (2005) 1.52
Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol (2011) 1.51
Estimation efficiency and statistical power in arterial spin labeling fMRI. Neuroimage (2006) 1.50
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol (2013) 1.47
Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A (2013) 1.46
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
Power calculation for group fMRI studies accounting for arbitrary design and temporal autocorrelation. Neuroimage (2007) 1.45
Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler (2012) 1.45
Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol (2010) 1.44
Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry (2009) 1.44
Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res (2008) 1.43
Rank-order versus mean based statistics for neuroimaging. Neuroimage (2007) 1.43
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol (2008) 1.43
Adjusting the effect of nonstationarity in cluster-based and TFCE inference. Neuroimage (2010) 1.42
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
False positives in neuroimaging genetics using voxel-based morphometry data. Neuroimage (2010) 1.39
Arterialization of cerebral veins on dynamic MDCT angiography: a possible sign of a dural arteriovenous fistula. AJR Am J Roentgenol (2005) 1.37
Genetics of the connectome. Neuroimage (2013) 1.33